[Edaravone in patients with amyotrophic lateral sclerosis]

Groppo J, García Martí S, Argento F, Alfie V, Bardach A, Ciapponi A, Augustovski F, Alcaraz A, Pichon-Riviere A
Record ID 32018004392
English, Spanish
Original Title: Edaravone en pacientes con esclerosis lateral amiotrófica
Authors' recommendations: High-quality evidence shows that edaravone decreases amyotrophic lateral sclerosis (ALS) progression, as assessed by a functional assessment scale. No studies assessing harder endpoints such as mortality, survival or quality of life have been found.In general, it is not paid by national coverage agencies from countries in Europe, Latin-America, Canada and Argentina; however some of the private funders from the United States surveyed cover it. There is only one cost-effectiveness study found carried out in Canada and concludes that edaravone is not cost-effective in any ALS stage in view of its high cost.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Amyotrophic Lateral Sclerosis
  • Edaravone
  • Free Radical Scavengers
  • Neuroprotective Agents
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.